State Street Corp Buys 111,291 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

State Street Corp increased its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 27.8% during the 3rd quarter, Holdings Channel reports. The fund owned 512,313 shares of the biotechnology company’s stock after acquiring an additional 111,291 shares during the period. State Street Corp’s holdings in Capricor Therapeutics were worth $7,792,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of CAPR. Main Street Financial Solutions LLC raised its holdings in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the period. SG Americas Securities LLC bought a new stake in Capricor Therapeutics in the 3rd quarter valued at about $133,000. Rhumbline Advisers acquired a new position in Capricor Therapeutics during the 2nd quarter worth approximately $147,000. The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics in the third quarter worth approximately $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new stake in Capricor Therapeutics in the third quarter valued at approximately $192,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald upped their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler started coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock. Oppenheimer reiterated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. Maxim Group upped their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $14.08 on Friday. The company has a market capitalization of $640.22 million, a price-to-earnings ratio of -13.28 and a beta of 3.98. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40. The company has a 50-day simple moving average of $17.46 and a two-hundred day simple moving average of $10.51.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.